Compare SCOR & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | CALC |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 9.7M |
| IPO Year | 2007 | 2020 |
| Metric | SCOR | CALC |
|---|---|---|
| Price | $6.27 | $0.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 10.8K | ★ 126.0K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.37 | N/A |
| EPS | ★ 4.25 | 0.30 |
| Revenue | ★ $403,549,000.00 | N/A |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $7.30 | N/A |
| P/E Ratio | ★ $1.53 | $2.18 |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $4.39 | $0.46 |
| 52 Week High | $10.18 | $7.20 |
| Indicator | SCOR | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 47.64 |
| Support Level | $6.22 | $0.50 |
| Resistance Level | $7.07 | $0.78 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 8.92 | 46.51 |
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.